The analyst is optimistic about the company's two clinical programs:
Anti-CEACAM1 monoclonal antibody CM24 for pancreatic ductal adenocarcinoma (PDAC).
NT219, the company's insulin receptor substrate 1/2 and STAT3 dual inhibitor small molecule, being developed initially to treat head and neck squamous cell carcinoma (HNSCC).
Both programs have shown supportive safety in the clinic and early signs of clinical activity to support further investigation.
The company expects multiple data readouts from its programs over the next 12 months that could de-risk its development candidates.
Chardan forecasts CM24 and NT219 reaching the U.S. market in 2027 and achieving probability-adjusted global sales in 2030E of $147 million and $61.7 million, respectively.
Price Action: PPBT shares are down 5.29% at $2.15 on the last check Thursday.
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.